GlassScriptPhysician profile
Mohummed Khani
NPI 1508022740
$997.27
in general payments reported to CMS, 2019-2025
10 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.32 · 2020: $12.72 · 2021: $32.63 · 2022: $464 · 2023: $45.56 · 2024: $95.79 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $463.70 | 2022 | |
| Medtronic, INC. | $277.40 | 2024-2025 | Ligasure |
| Intuitive Surgical, INC. | $71.19 | 2023-2025 | Da Vinci Surgical System |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Baxter Healthcare | $40.32 | 2024 | Perclot |
| Thd America, INC. | $35.72 | 2021-2023 | |
| Activ Surgical, INC. | $20.48 | 2024 | Activsight |
| Baudax Bio INC. | $17.94 | 2021 | |
| Acell, INC. | $12.72 | 2020 | |
| Kerecis Limited | $4.48 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohummed Khani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.